Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
Sign Up to like & getrecommendations! Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0665-2
Abstract: BackgroundThe safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies.MethodsMEDI0680 was administered intravenously once every 2 weeks (Q2W) or… read more here.
Keywords: phase; advanced solid; solid malignancies; study ... See more keywords